The Glut1 Deficiency Syndrome (GLUT1DS or De Vivo Disease) is a rare neuro-metabolic disease caused by the impairment of glucose transporter 1 (GLUT1) that provokes glucose starvation of brain neurons. It is characterized by a wide clinical variability and affects more severely children who can suffer from epilepsy, movement disorders and/or intellectual disabilities. The correct diagnosis is difficult to establish timely and limitations in current diagnostic practice are responsible for medical wandering with dramatic consequences, although a cure exists (ketogenic diet).

“Early identification of children is important in order to avoid submitting them to possibly ineffective or potentially detrimental treatments with anticonvulsants” (1)

Because time matters

“*It is essential to diagnose as early as possible to allow prompt compensation, through the Ketogenic Diet, for the brain’s lack of fuel...*”

Puzzled by these neurological symptoms?

- Intractable epilepsy
- Movement disorders
- Developmental delays

...think GLUT1DS

METAglut1™ an innovative blood test to fight misdiagnosis and medical wandering at the earliest

METAglut1 is an in Vitro Diagnostic Medical Device used to aid in the diagnosis of the GLUT1 Deficiency Syndrome (GLUT1DS). It is a regulated health product that, under this regulation, bears the CE mark.
METAglut1 provides a **simple** way to find GLUT1DS patients **faster** and **accurately**

- **An underdiagnosed disease:**
  of estimated ca. 12,000 cases of GLUT1DS in EU and the USA, most remain undiagnosed \(^2\)

- **Several complex symptoms** can be a clue of a GLUT1DS condition \(^3\):
  - Intractable epilepsy, in particular early onset absence epilepsy
  - Global developmental delay, particularly in speech
  - Complex movement disorders, paroxysmal events triggered by exercise

**METAglut1™**
**an innovative test, made available for daily clinical use**

(Published in Gras et al., Annals of Neurology 2017)

- **Quick turnaround time** (24-72hrs.)
- **A simple blood draw, no need for fasting**
- **Accurate and affordable** \(^4\)

**How to prescribe METAglut1™ in routine clinical practice?**

- **Already available** in France and Benelux through Laboratoire Cerba
  www.lab-cerba.com
  Benefits from an exceptional, fast track reimbursement in France through the **Forfait Innovation Scheme**

Soon in your country, send us an email:
> metaglut1@metafora-biosystems.com

---

**About METAFORA**

Metafora biosystems develops a platform for the discovery, development and distribution of blood tests that detect abnormalities in cellular energetics. Using RBDs (Receptor Binding Domains), patented reagents that quantify cell nutrient transporters, coupled with powerful algorithms, the flow cytometry platform is able to detect abnormal nutrient consumption that may be the cause of illnesses such as neuro-metabolic diseases, cancer or inflammatory disorders.

---

2/ Pr Darryl DeVivo, Columbia Medical School, personal communication
3/ J. Klepper - Developmental Medicine & Child Neurology 2015, 57: 890-8
4/ Sensitivity = 77%, specificity > 99,5%

---

**METAFORA biosystems**
**Pépinière Paris Biotech Santé**
29 rue du Faubourg Saint Jacques
75014 Paris • FRANCE

tel. +33 (0) 9 61 62 65 17
contact@metafora-biosystems.com
www.metafora-biosystems.com